OncoCyte (OCX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

OCX Stock Forecast

OncoCyte stock forecast is as follows: an average price target of $8.08 (represents a 268.95% upside from OCX’s last price of $2.19) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

OCX Price Target

The average price target for OncoCyte (OCX) is $8.08 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $4.25. This represents a potential 268.95% upside from OCX's last price of $2.19.

OCX Analyst Ratings

Buy

According to 4 Wall Street analysts, OncoCyte's rating consensus is 'Buy'. The analyst rating breakdown for OCX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

OncoCyte Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 24, 2024	Mike Matson	Needham	$4.25	$2.38	78.57%	94.06%
Dec 01, 2022		Lake Street	$10.00	$9.44	5.95%	356.62%
Nov 18, 2022		Piper Sandler	$10.00	$8.52	17.32%	356.62%
Aug 17, 2022	David Westenberg	Piper Sandler	$30.00	$17.48	71.61%	1269.86%
Aug 11, 2022		Lake Street	$60.00	$19.27	211.30%	2639.73%
Aug 11, 2022		Needham	$42.00	$19.02	120.84%	1817.81%
May 15, 2022	David Westenberg	Piper Sandler	$28.00	$22.60	23.89%	1178.54%

The latest OncoCyte stock forecast, released on Apr 24, 2024 by Mike Matson from Needham, set a price target of $4.25, which represents a 78.57% increase from the stock price at the time of the forecast ($2.38), and a 94.06% increase from OCX last price ($2.19).

OncoCyte Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$4.25
Last Closing Price	$2.19	$2.19	$2.19
Upside/Downside	-100.00%	-100.00%	94.06%

In the current month, the average price target of OncoCyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OncoCyte's last price of $2.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 15, 2024	Needham	Buy	Buy	Hold
May 16, 2024	Stephens	Buy	Buy	Hold
Apr 24, 2024	Needham	Buy	Buy	Hold
Nov 18, 2022	Piper Sandler	Overweight	Neutral	Downgrade
Nov 14, 2022	Piper Sandler	Overweight	Overweight	Hold
Nov 11, 2022	Needham	Buy	Buy	Hold
Aug 17, 2022	Piper Sandler	Overweight	Overweight	Hold
Aug 11, 2022	Lake Street	Buy	Buy	Hold
Aug 11, 2022	Needham	Buy	Buy	Hold
May 15, 2022	Piper Sandler	Overweight	Overweight	Hold
May 12, 2022	Needham	Buy	Buy	Hold

OncoCyte's last stock rating was published by Needham on Oct 15, 2024. The company gave OCX a "Buy" rating, the same as its previous rate.

OncoCyte Financial Forecast

OncoCyte Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20	Mar 18	Mar 16
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$429.00K	-	$297.00K	$-3.55M	$1.02M	$2.07M	$1.42M	$3.59M	$984.00K	$2.03M	$1.12M	$503.00K	$555.00K	$16.00K	-	-
Avg Forecast	$1.88M	$1.54M	$1.29M	$1.01M	$516.20K	$203.03K	$177.13K	$143.37K	$101.67K	$178.33K	$318.55K	$350.00K	$225.00K	$312.50K	$362.50K	$346.40K	$1.48M	$2.71M	$2.24M	$3.52M	$1.75M	$1.57M	$838.02K	$807.90K	$366.67K	$47.20K	$13.54K	$55.00K	$4.33K
High Forecast	$2.21M	$1.81M	$1.51M	$1.19M	$605.03K	$237.97K	$207.61K	$180.85K	$105.00K	$209.02K	$318.77K	$410.23K	$263.72K	$312.75K	$424.88K	$406.01K	$1.74M	$2.71M	$2.24M	$3.52M	$1.75M	$1.57M	$838.02K	$807.90K	$366.67K	$47.20K	$16.25K	$66.00K	$5.20K
Low Forecast	$1.57M	$1.29M	$1.07M	$846.06K	$430.66K	$169.39K	$147.78K	$105.89K	$100.00K	$148.78K	$318.32K	$292.00K	$187.72K	$312.25K	$302.43K	$289.00K	$1.24M	$2.71M	$2.24M	$3.52M	$1.75M	$1.57M	$838.02K	$807.90K	$366.67K	$47.20K	$10.83K	$44.00K	$3.46K
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	4	7	4	4	4	6	9	16	10
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.37%	-	0.86%	-2.39%	0.38%	0.92%	0.40%	2.05%	0.63%	2.42%	1.39%	1.37%	11.76%	1.18%	-	-

OncoCyte's average Quarter revenue forecast for Dec 23 based on 2 analysts is $225.00K, with a low forecast of $187.72K, and a high forecast of $263.72K. OCX's average Quarter revenue forecast represents a -47.55% decrease compared to the company's last Quarter revenue of $429.00K (Sep 23).

OncoCyte EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20	Mar 18	Mar 16
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	4	7	4	4	4	6	9	16	10
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-6.51M	-	$-6.17M	$13.45M	$-13.38M	$-14.64M	$-13.37M	$-34.66M	$-12.55M	$-10.77M	$-10.96M	$-6.19M	$-5.78M	$-8.58M	$-3.55M	$-2.85M
Avg Forecast	$-1.13M	$-925.95K	$-772.53K	$-608.46K	$-309.72K	$-121.82K	$-106.28K	$-86.02K	$-61.00K	$-107.00K	$-191.13K	$-8.57M	$-135.00K	$-187.50K	$-217.50K	$-9.16M	$-2.52M	$-1.62M	$-1.34M	$-9.80M	$-1.05M	$-944.14K	$-502.81K	$-14.80M	$-220.00K	$-28.32K	$-7.02M	$-3.40M	$-3.08M
High Forecast	$-942.33K	$-772.51K	$-644.52K	$-507.63K	$-258.40K	$-101.63K	$-88.67K	$-63.53K	$-60.00K	$-89.27K	$-191.00K	$-6.85M	$-112.63K	$-187.35K	$-181.46K	$-7.33M	$-2.01M	$-1.62M	$-1.34M	$-7.84M	$-1.05M	$-944.14K	$-502.81K	$-11.84M	$-220.00K	$-28.32K	$-5.61M	$-2.72M	$-2.46M
Low Forecast	$-1.32M	$-1.09M	$-905.47K	$-713.17K	$-363.02K	$-142.78K	$-124.57K	$-108.51K	$-63.00K	$-125.41K	$-191.26K	$-10.28M	$-158.23K	$-187.65K	$-254.93K	$-11.00M	$-3.02M	$-1.62M	$-1.34M	$-11.76M	$-1.05M	$-944.14K	$-502.81K	$-17.76M	$-220.00K	$-28.32K	$-8.42M	$-4.08M	$-3.70M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	34.74%	-	0.67%	-5.35%	8.24%	10.89%	1.36%	32.95%	13.30%	21.41%	0.74%	28.15%	204.06%	1.22%	1.04%	0.93%

1 analysts predict OCX's average Quarter EBITDA for Mar 23 to be $-9.16M, with a high of $-7.33M and a low of $-11.00M. This is -168.13% lower than OncoCyte's previous annual EBITDA (Dec 22) of $13.45M.

OncoCyte Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20	Mar 18	Mar 16
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	4	7	4	4	4	6	9	16	10
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-6.69M	-	$3.03M	$-45.34M	$-9.45M	$-8.04M	$-10.69M	$-35.88M	$-13.80M	$-10.49M	$-3.92M	$-6.31M	$-6.78M	$-7.73M	$-3.78M	$-2.93M
Avg Forecast	$-4.23M	$-4.47M	$-4.69M	$-5.12M	$-5.53M	$-5.62M	$-5.99M	$-5.76M	$-5.85M	$-5.99M	$-7.68M	$-9.75M	$-9.60M	$-13.83M	$-17.79M	$-10.42M	$-2.61M	$-30.89M	$-31.26M	$-11.15M	$-29.61M	$-25.88M	$-25.41M	$-5.29M	$-24.88M	$-26.77M	$-6.33M	$-3.43M	$-3.15M
High Forecast	$-3.32M	$-3.50M	$-3.68M	$-4.02M	$-4.34M	$-4.41M	$-4.70M	$-4.94M	$-4.60M	$-4.70M	$-6.03M	$-7.80M	$-7.53M	$-10.85M	$-13.96M	$-8.34M	$-2.09M	$-30.89M	$-31.26M	$-8.92M	$-29.61M	$-25.88M	$-25.41M	$-4.23M	$-24.88M	$-26.77M	$-5.06M	$-2.75M	$-2.52M
Low Forecast	$-5.18M	$-5.47M	$-5.73M	$-6.26M	$-6.77M	$-6.88M	$-7.33M	$-6.58M	$-7.11M	$-7.33M	$-9.40M	$-11.70M	$-11.75M	$-16.92M	$-21.77M	$-12.51M	$-3.13M	$-30.89M	$-31.26M	$-13.38M	$-29.61M	$-25.88M	$-25.41M	$-6.35M	$-24.88M	$-26.77M	$-7.59M	$-4.12M	$-3.78M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.48%	-	-0.29%	17.36%	0.31%	0.26%	0.96%	1.21%	0.53%	0.41%	0.74%	0.25%	0.25%	1.22%	1.10%	0.93%

OncoCyte's average Quarter net income forecast for Jun 23 is $-17.79M, with a range of $-21.77M to $-13.96M. OCX's average Quarter net income forecast represents a -686.68% decrease compared to the company's last Quarter net income of $3.03M (Mar 23).

OncoCyte SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20	Mar 18	Mar 16
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	4	7	4	4	4	6	9	16	10
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.20M	-	$4.11M	$-4.00M	$9.21M	$9.03M	$8.89M	$7.45M	$8.43M	$10.61M	$7.02M	$5.28M	$6.56M	$6.12M	$2.44M	$1.24M
Avg Forecast	$21.65M	$17.75M	$14.81M	$11.66M	$5.94M	$2.34M	$2.04M	$1.65M	$1.17M	$2.05M	$3.66M	$4.03M	$2.59M	$3.59M	$4.17M	$3.98M	$1.40M	$31.28M	$25.91M	$40.74M	$20.27M	$18.19M	$9.69M	$9.34M	$4.24M	$545.66K	$156.51K	$635.84K	$50.09K
High Forecast	$25.38M	$20.81M	$17.36M	$13.67M	$6.96M	$2.74M	$2.39M	$2.08M	$1.21M	$2.40M	$3.67M	$4.72M	$3.03M	$3.60M	$4.89M	$4.67M	$1.68M	$31.28M	$25.91M	$40.74M	$20.27M	$18.19M	$9.69M	$9.34M	$4.24M	$545.66K	$187.80K	$763.01K	$60.09K
Low Forecast	$18.06M	$14.81M	$12.36M	$9.73M	$4.95M	$1.95M	$1.70M	$1.22M	$1.15M	$1.71M	$3.66M	$3.36M	$2.16M	$3.59M	$3.48M	$3.32M	$1.12M	$31.28M	$25.91M	$40.74M	$20.27M	$18.19M	$9.69M	$9.34M	$4.24M	$545.66K	$125.19K	$508.67K	$40.06K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.89%	-	1.03%	-2.86%	0.29%	0.35%	0.22%	0.37%	0.46%	1.09%	0.75%	1.25%	12.03%	39.07%	3.85%	24.81%

OncoCyte's average Quarter SG&A projection for Dec 23 is $2.59M, based on 2 Wall Street analysts, with a range of $2.16M to $3.03M. The forecast indicates a -19.13% fall compared to OCX last annual SG&A of $3.20M (Sep 23).

OncoCyte EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20	Mar 18	Mar 16
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	4	7	4	4	4	6	9	16	10
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.81	-	$0.02	$-0.41	$-0.08	$-0.07	$-0.12	$-0.39	$-0.15	$-0.12	$-0.05	$-0.09	$-0.10	$-0.13	$-0.12	$-0.12
Avg Forecast	$-0.31	$-0.33	$-0.34	$-0.37	$-0.40	$-0.41	$-0.44	$-0.42	$-0.43	$-0.44	$-0.56	$-0.67	$-0.70	$-1.01	$-1.30	$-1.80	$-2.27	$-2.40	$-2.43	$-2.46	$-2.30	$-2.01	$-1.97	$-2.15	$-1.93	$-2.08	$-1.76	$-0.10	$-0.14
High Forecast	$-0.24	$-0.26	$-0.27	$-0.29	$-0.32	$-0.32	$-0.34	$-0.36	$-0.34	$-0.34	$-0.44	$-0.53	$-0.55	$-0.79	$-1.02	$-1.41	$-1.78	$-2.40	$-2.43	$-2.46	$-2.30	$-2.01	$-1.97	$-2.15	$-1.93	$-2.08	$-1.76	$-0.08	$-0.11
Low Forecast	$-0.38	$-0.40	$-0.42	$-0.46	$-0.49	$-0.50	$-0.53	$-0.48	$-0.52	$-0.53	$-0.69	$-0.82	$-0.86	$-1.23	$-1.59	$-2.20	$-2.77	$-2.40	$-2.43	$-2.46	$-2.30	$-2.01	$-1.97	$-2.15	$-1.93	$-2.08	$-1.76	$-0.12	$-0.17
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.80%	-	-0.01%	0.18%	0.03%	0.03%	0.05%	0.17%	0.07%	0.06%	0.02%	0.05%	0.05%	0.07%	1.20%	0.86%

According to 1 Wall Street analysts, OncoCyte's projected average Quarter EPS for Jun 23 is $-1.30, with a low estimate of $-1.59 and a high estimate of $-1.02. This represents a -6587.50% decrease compared to OCX previous annual EPS of $0.02 (Mar 23).

OncoCyte Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PRPH	ProPhase Labs	$0.69	$14.00	1928.99%	Hold
DRIO	DarioHealth	$0.71	$10.75	1414.08%	Buy
STIM	Neuronetics	$1.30	$8.00	515.38%	Buy
OCX	OncoCyte	$2.21	$8.08	265.61%	Buy
BDSX	Biodesix	$1.39	$3.00	115.83%	Buy
PSNL	Personalis	$3.84	$7.38	92.19%	Hold
CSTL	Castle Biosciences	$28.14	$40.50	43.92%	Buy
SHC	Sotera Health Company	$13.08	$16.00	22.32%	Buy
XGN	Exagen	$5.80	$5.00	-13.79%	Buy

OCX Forecast FAQ

Is OncoCyte a good buy?

Yes, according to 4 Wall Street analysts, OncoCyte (OCX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of OCX's total ratings.

What is OCX's price target?

OncoCyte (OCX) average price target is $8.08 with a range of $4.25 to $10, implying a 268.95% from its last price of $2.19. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will OncoCyte stock go up soon?

According to Wall Street analysts' prediction for OCX stock, the company can go up by 268.95% (from the last price of $2.19 to the average price target of $8.08), up by 356.62% based on the highest stock price target, and up by 94.06% based on the lowest stock price target.

Can OncoCyte stock reach $3?

OCX's average twelve months analyst stock price target of $8.08 supports the claim that OncoCyte can reach $3 in the near future.

What are OncoCyte's analysts' financial forecasts?

OncoCyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.04M (high $1.23M, low $853.72K), average EBITDA is $-624K (high $-512K, low $-739K), average net income is $-22.902M (high $-18.387M, low $-27.56M), average SG&A $11.96M (high $14.16M, low $9.82M), and average EPS is $-1.67 (high $-1.341, low $-2.01). OCX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.73M (high $6.71M, low $4.78M), average EBITDA is $-3.436M (high $-2.867M, low $-4.028M), average net income is $-18.502M (high $-14.517M, low $-22.641M), average SG&A $65.88M (high $77.21M, low $54.96M), and average EPS is $-1.349 (high $-1.059, low $-1.651).

Did the OCX's actual financial results beat the analysts' financial forecasts?

Based on OncoCyte's last annual report (Dec 2022), the company's revenue was $958K, which missed the average analysts forecast of $9.96M by -90.38%. Apple's EBITDA was $-30.399M, beating the average prediction of $-15.284M by 98.89%. The company's net income was $-73.44M, missing the average estimation of $-75.903M by -3.25%. Apple's SG&A was $23.01M, missing the average forecast of $99.33M by -76.83%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-9.552 by -93.09%. In terms of the last quarterly report (Sep 2023), OncoCyte's revenue was $429K, beating the average analysts' forecast of $312.5K by 37.28%. The company's EBITDA was $-6.513M, beating the average prediction of $-188K by 3373.60%. OncoCyte's net income was $-6.687M, missing the average estimation of $-13.829M by -51.64%. The company's SG&A was $3.2M, missing the average forecast of $3.59M by -10.97%. Lastly, the company's EPS was $-0.81, missing the average prediction of $-1.008 by -19.67%